EN | RU
EN | RU

Help Support

Back

Usefulness of Enterococcus faecium and Bacillus subtilis as an adjuvant to conventional IBS therapies

Irritable bowel syndrome Irritable bowel syndrome
Irritable bowel syndrome Irritable bowel syndrome

Several clinical studies published in Chinese support the utilization of Medilac-S (non-commercially known as IBacilluS+) as a supplementary treatment in diverse conditions, encompassing ulcerative colitis, irritable bowel syndrome (IBS), acute gastritis, and Helicobacter pylori (H. pylori) therapy.

See All

Key take away

Medilac-S (Enterococcus faecium R0026 and Bacillus subtilis R0179) is a safe and efficient adjuvant to irritable bowel syndrome conventional medications.

Background

Several clinical studies published in Chinese support the utilization of Medilac-S (non-commercially known as IBacilluS+) as a supplementary treatment in diverse conditions, encompassing ulcerative colitis, irritable bowel syndrome (IBS), acute gastritis, and Helicobacter pylori (H. pylori) therapy.

To consolidate findings from these studies, a systematic review with a meta-analysis was carried out to assess the effectiveness of this probiotic formulation as a complement to traditional IBS agents.

Method

A comprehensive search across 6 international and Chinese databases revealed 37 eligible studies, of which 33 investigated the benefits of Medilac-S as an adjunct therapy utilizing a standardized categorical scale. These 33 studies were incorporated in the meta-analysis, employing a random-effect model stratified by the IBS subtype.

Result

As found, Medilac-S remarkably enhanced the efficiency of conventional IBS therapy (RR = 1.21; 95% CI: 1.17–1.25), indicating a 21% greater likelihood of therapeutic success with the probiotic adjuvant, irrespective of the subtype. Adverse events, noted in 78% of the trials, were predominantly mild-to-moderate and self-resolving, with comparable incidence rates in the probiotic adjuvant (6.2%; n = 1347) and control (5.9%; n = 1331) groups.

Conclusion

The outcomes reinforced the conclusion that Medilac-S serves as a safe and effective supplementary option alongside various conventional treatments for IBS sufferers.

Source:

Gastroenterology Insights

Article:

Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis

Authors:

Annie Tremblay et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: